Rb inactivation casts some doubt on the clinical utility of CDK inhibition, as Rb inactivation affects the CDK pathway downstream of CDKs, presenting a potential mechanism of both primary and secondary resistance to CDKi in LMS, similarly to Rb-mediated resistance mechanisms in CDK-treated breast cancer patients (37). The gene discussed is RB1; the disease is breast carcinoma.